179 related articles for article (PubMed ID: 37097388)
1. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
2. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
[TBL] [Abstract][Full Text] [Related]
3. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
4. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
[TBL] [Abstract][Full Text] [Related]
5. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Zacholski K; Hambley B; Hickey E; Kashanian S; Li A; Baer MR; Duong VH; Newman MJ; DeZern A; Gojo I; Smith BD; Levis MJ; Varadhan R; Gehrie E; Emadi A; Ghiaur G
J Oncol Pharm Pract; 2022 Sep; 28(6):1340-1349. PubMed ID: 34134554
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
Jen WY; Sasaki K; Rausch CR; DiNardo CD; Kadia TM; Yilmaz M; Borthakur G; Alvarado Y; McCue D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2024 Mar; 65(3):378-382. PubMed ID: 38054837
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
Barsoum B; Henneman A; Ahmad S; Ghiuzeli C
Leuk Lymphoma; 2021 Mar; 62(3):703-708. PubMed ID: 33107373
[TBL] [Abstract][Full Text] [Related]
11. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
12. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
16. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
Zhang X; Wu S; Yang J; Zhang G; Su Y; Zhang M; He J; Shi Y; Li W; Lu P; Lu D
Int J Hematol; 2023 Apr; 117(4):530-537. PubMed ID: 36580227
[TBL] [Abstract][Full Text] [Related]
17. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
18. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma H; Yang J
Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330
[TBL] [Abstract][Full Text] [Related]
19. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
